Initial treatment of B‐cell prolymphocytic leukemia with ibrutinib

Moore, Jeremiah; Baran, Andrea; Meacham, Philip J; Evans, Andrew; Barr, Paul M.; Zent, Clive S.

doi:10.1002/ajh.25733

Cited by 9 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Front‐line treatment with rituximab and idelalisib has demonstrated a response rate of 100% in eight patients treated in the United Kingdom but substantial immune and infection‐related toxicity was noteworthy in this cohort 3 . The efficacy of ibrutinib monotherapy is limited to case reports with some transient efficacy seen 4,5 . Finally, a single case report described a minimal residual disease (MRD) undetectable remission of 3 years with the combination of ibrutinib and venetoclax 6 .…”

Section: Figurementioning

confidence: 93%

See 1 more Smart Citation

Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia

Chen

Eyre

2022

European J of Haematology

View full text Add to dashboard Cite

B‐cell prolymphocytic leukaemia (B‐PLL) is an aggressive B‐cell lymphoproliferative disease with few clinically proven targeted treatments. Due to the rarity of the condition, there is a paucity of clinical trial data and none that involve targeted inhibitors. We present a unique case of relapsed refractory B‐PLL treated to a sustained minimal residual disease‐negative remission with venetoclax monotherapy, to add to the current evidence base and rationale for future studies using BCL‐2 inhibitors in B‐PLL.

show abstract

Section: Figurementioning

confidence: 93%

“…3 The efficacy of ibrutinib monotherapy is limited to case reports with some transient efficacy seen. 4,5 Finally, a single case report described a minimal residual disease (MRD) undetectable remission of 3 years with the combination of ibrutinib and venetoclax. 6 As a result, the evidence base to guide treatment decisions is extremely limited.…”

mentioning

confidence: 99%

Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia

Chen

Eyre

2022

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…The time to first treatment (TFT) was defined as time from diagnosis to first therapy in asymptomatic B-PLL. Response to therapy was evaluated using modified criteria from those of iwCLL 9,14 . Baseline characteristics are described as median and range for continuous variables and frequency and percentage for categorical variables.…”

Section: List Of Members Of Filo Groupmentioning

confidence: 99%

Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Ibrutinib remains a viable therapeutic option for rare indolent lymphomas such as B-PLL which have a higher TP53 mutation positivity. [72] Similarly, variant HCL which is relatively resistant to cladribine, responds well to ibrutinib. [73] This versatile drug has also shown some efficacy in relapsed PCNSL.…”

Section: Other Malignanciesmentioning

confidence: 99%

Drug Review: Ibrutinib

Karunakaran

2020

Indian Journal of Medical and Paediatric Oncology

View full text Add to dashboard Cite

Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are refractory to conventional chemoimmunotherapy. This small-molecule inhibitor has shown efficacy in this difficult-to-treat subset – those with del(17p)/TP53-mutated CLL. Its immunomodulatory properties make it an excellent choice for combining with other immunotherapeutic agents such as venetoclax. The drug is not without drawbacks. The need for indefinite therapy and the presence of adverse effects such as infection, bleeding, hypertension, and arrhythmia temper our enthusiasm for this versatile drug. But overall, ibrutinib's favorable risk profile and lack of myelosuppression make it an ideal therapy for the elderly and those with multiple comorbidities.

show abstract

Initial treatment of B‐cell prolymphocytic leukemia with ibrutinib

Cited by 9 publications

References 5 publications

Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia

Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia

Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)

Drug Review: Ibrutinib

Contact Info

Product

Resources

About